Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | OMP-336B11 |
Synonyms | |
Therapy Description |
OMP-336B11 is a fusion protein consisting GITRL (glucocorticoid-nduced tumor necrosis factor receptor ligand, TNFSF18) and the Fc domain of immunoglobulin, which activates GITR signaling and promotes anti-tumor immunity (Cancer Res 2017;77(13 Suppl): Abstract nr 5621). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OMP-336B11 | GITRL-Fc|OMP 336B11 | OMP-336B11 is a fusion protein consisting GITRL (glucocorticoid-nduced tumor necrosis factor receptor ligand, TNFSF18) and the Fc domain of immunoglobulin, which activates GITR signaling and promotes anti-tumor immunity (Cancer Res 2017;77(13 Suppl): Abstract nr 5621). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03295942 | Phase I | OMP-336B11 | A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors | Terminated | USA | 0 |